# An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Study · id `cardio:ct-nct01560637` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01560637](<https://clinicaltrials.gov/study/NCT01560637>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01560637

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 471 participants.

## Technical summary

Registry record NCT01560637. Allocation not applicable; no masking; primary purpose treatment. Start 2013-09-11 (actual); primary completion 2021-08-12 (actual). Results posted on 2022-06-02.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 471 participants (enrolled count; ClinicalTrials.gov record NCT01560637, source copy `cardio:ctgov-nct01560637-2022-06-02`, retrieved 2026-10-31)
- Started: 2013-09-11 (actual) (ClinicalTrials.gov record NCT01560637, source copy `cardio:ctgov-nct01560637-2022-06-02`, retrieved 2026-10-31)
- Primary completion: 2021-08-12 (actual) (ClinicalTrials.gov record NCT01560637, source copy `cardio:ctgov-nct01560637-2022-06-02`, retrieved 2026-10-31)
- Completion: 2021-08-12 (actual) (ClinicalTrials.gov record NCT01560637, source copy `cardio:ctgov-nct01560637-2022-06-02`, retrieved 2026-10-31)
- Results first posted: 2022-06-02 (ClinicalTrials.gov record NCT01560637, source copy `cardio:ctgov-nct01560637-2022-06-02`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Brazil; Canada; Chile; China; Denmark; France; Germany; Greece; India; Israel; Italy; Mexico; Netherlands; Poland; Singapore; South Korea; Sweden; Taiwan; United Kingdom (ClinicalTrials.gov record NCT01560637, source copy `cardio:ctgov-nct01560637-2022-06-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01560637-2022-06-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): UT-15C (treprostinil diolamine)
- Lead sponsor: United Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: United Therapeutics (`cardio:org-united-therapeutics`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension (`cardio:pubmed-38055186`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b30a07517fbd221366b48e57c350dccf0815b5a6b19a5fcbe256c9a8b6032dfc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
